title: Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein.
abstract: The prevalence and clinical significance of antibodies against beta2-glycoprotein I (anti-beta2GPI) and antibodies against oxidized low-density lipoprotein (anti-ox-LDL) were evaluated as potential indicators of arterial disease in patients with systemic lupus erythematosus (SLE) and SLE with secondary antiphospholipid syndrome (APS). IgG anti-beta2GPI and IgG anti-ox-LDL were measured by enzyme-linked immunosorbent assay (ELISA) in serum samples from 118 patients with SLE, including 40 with secondary APS. IgG anti-beta2GPI were positive in 17% (20/118) of SLE patients. The presence and titres of IgG anti-beta2GPI were strongly associated with a history of arterial thrombosis. Haemolytic anaemia was also significantly associated with the presence of IgG anti-beta2GPI. The prevalence of IgG anti-ox-LDL was 53% (63/118), but there was no association with arterial thrombosis. No correlation between the values of anti-ox-LDL and those of anti-beta2GPI was found. These results suggest that IgG anti-beta2GPI could be a marker for arterial thrombosis in SLE patients, while IgG anti-ox-LDL were not associated with arterial disease in this group of lupus patients.
authors.affiliation: Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London.
authors.forename: F I
authors.initials: FI
authors.lastname: Romero
authors.forename: O
authors.initials: O
authors.lastname: Amengual
authors.forename: T
authors.initials: T
authors.lastname: Atsumi
authors.forename: M A
authors.initials: MA
authors.lastname: Khamashta
authors.forename: F J
authors.initials: FJ
authors.lastname: Tinahones
authors.forename: G R
authors.initials: GR
authors.lastname: Hughes
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000276:immunology*; D001053:Apolipoproteins / Q000276:immunology*; D001161:Arteriosclerosis / Q000209:etiology*; D001323:Autoantibodies / Q000276:immunology*; D002648:Child; D005260:Female; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology* / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D053482:beta 2-Glycoprotein I
chemical_list: D001053:Apolipoproteins; D001323:Autoantibodies; D006023:Glycoproteins; D008077:Lipoproteins, LDL; D053482:beta 2-Glycoprotein I